Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
BUSINESS
Foreign Drug Makers’ Sales Dip on Generic Inroads in 2014
Combined sales of 11 major non-Japanese drug makers in Japan slipped 1.8% in 2014 compared to the previous year, resulting in lower profits, according to a Jiho tally. The decline, chiefly blamed on the NHI drug price revision implemented in…
To read the full story
Related Article
- AstraZeneca Tops Foreign Pharma Ranking in 2021, Pfizer Sales Undisclosed: Jiho
May 27, 2022
- Eli Lilly Japan Sales Cross 200 Billion Yen in 2014, Top 10 Eyed by 2020
April 9, 2015
- Bayer Yakuhin Logs Double-Digit Growth for 2 Years Running on Xarelto
April 8, 2015
- Sanofi Japan Sales Dip 7.6% on Generic Erosion though Plavix Grew
April 3, 2015
- AZ to Tap Rich Pipelines to Grow as Oncology Powerhouse
March 11, 2015
- MSD Japan Sales Down 14%, Januvia Sags 6.7%
March 6, 2015
- Pfizer Japan Sales Down 5% as Generic Erosion Weighs
March 5, 2015
- 2013 Earnings Signal Foreign Drug Makers Losing Steam in Japan
June 2, 2014
- Foreign Drug Makers’ Japan Units Underperform Market Growth in 2013
May 23, 2014
BUSINESS
- Mochida Lifts G-Lasta Biosimilar Shipment Curbs after Over 2 Years
November 4, 2026
- Espha Taps Korean Eylea Follow-On for First Biosimilar Foray
November 4, 2026
- Kyowa Kirin Won’t Stop Drug Launches over MFN Pricing: CEO
November 4, 2026
- Takara Bio, S-RACMO Finalize Cell Processing CDMO Transfer for January
November 4, 2026
- Roche Launches CDx for Takeda’s Elahere in Japan
November 4, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…